REFERENCES
1. Roerden M, Spranger S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol. 2025;25:353-69.
2. Aliazis K, Christofides A, Shah R, et al. The tumor microenvironment’s role in the response to immune checkpoint blockade. Nat Cancer. 2025;6:924-37.
3. Gong D, Arbesfeld-Qiu JM, Perrault E, Bae JW, Hwang WL. Spatial oncology: translating contextual biology to the clinic. Cancer Cell. 2024;42:1653-75.
4. Liu Y, Dai Y, Wang L. Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications. Cancer Cell. 2026;44:24-49.
5. Williams HL, Frei AL, Koessler T, et al. The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition. NPJ Precis Oncol. 2024;8:178.
6. Jing SY, Wang HQ, Lin P, Yuan J, Tang ZX, Li H. Quantifying and interpreting biologically meaningful spatial signatures within tumor microenvironments. NPJ Precis Oncol. 2025;9:68.
7. Nian Z, Dou Y, Shen Y, et al. Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation. Immunity. 2024;57:2344-2361.e7.
8. Ikeda H, Kawase K, Nishi T, et al. Immune evasion through mitochondrial transfer in the tumour microenvironment. Nature. 2025;638:225-36.
9. Liu H, Yang W, Jiang J. Targeting tumor metabolism to augment CD8+ T cell anti-tumor immunity. J Pharm Anal. 2025;15:101150.
10. Burr ML, Sparbier CE, Chan KL, et al. An evolutionarily conserved function of polycomb silences the MHC class i antigen presentation pathway and enables immune evasion in cancer. Cancer Cell. 2019;36:385-401.e8.
11. Peng D, Kryczek I, Nagarsheth N, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527:249-53.
12. Lemaitre L, Adeniji N, Suresh A, et al. Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease. Nat Cancer. 2024;5:1534-56.
13. Zhou W, Ye F, Yang G, et al. YAP-based nomogram predicts poor prognosis in patients with hepatocellular carcinoma after curative surgery. J Gastrointest Oncol. 2024;15:1712-22.
14. Adam-Artigues A, Valencia Salazar LE, Aguirre-Ghiso JA. Immune evasion by dormant disseminated cancer cells: a Fermi paradox? Cancer Cell. 2024;42:13-5.
15. Hu J, Sánchez-Rivera FJ, Wang Z, et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature. 2023;616:806-13.
16. Chu X, Li X, Zhang Y, et al. Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms. Nat Cancer. 2024;5:1409-26.
17. Derosa L, Iebba V, Silva CAC, et al. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. Cell. 2024;187:3373-3389.e16.
18. Trontzas IP, Syrigos KN. Immune biomarkers for checkpoint blockade in solid tumors: transitioning from tissue to peripheral blood monitoring and future integrated strategies. Cancers. 2025;17:2639.
19. Cottrell TR, Lotze MT, Ali A, et al. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols. J Immunother Cancer. 2025;13:e010928.
20. Lindsay JR, Altreuter J, Alessi JV, et al. Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment. Cell Rep Med. 2025:102418.
21. Greenwald NF, Nederlof I, Sowers C, et al. Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC. Nat Cancer. 2026;7:435-50.
22. Li D, Shao F, Yu Q, et al. The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways. Cell Commun Signal. 2024;22:405.
23. Sun L, Zhao G, Wang S, Li N. Immune cell metabolism in cancer drug resistance: advances in target discovery and clinical translation. Chin J Cancer Res. 2025;37:432-45.
24. Tufail M, Jiang CH, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther. 2025;10:227.
25. Sullivan RJ, Cillo AR, Ferris RL, et al. SITC vision: opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy. J Immunother Cancer. 2025;13:e011929.
26. Chen D, Wu R, Liu Z, Wei Y, Kuang D. Therapy-induced remodeling of the tumor immune microenvironment: Mechanistic insights and implications for immunotherapy. Chin Med J. 2026;139:1149-67.
27. Cho J. Understanding tumor dormancy: from experimental models to mechanisms and therapeutic strategies. Biomol Ther. 2025;33:770-84.
28. Pan J, Chen S, Jin L, Chen K, Ye Z, Li B. Immunotherapy-driven remodeling of the tumor immune microenvironment: Spatiotemporal heterogeneity and multidimensional dynamics. Biochim Biophys Acta Rev Cancer. 2026;1881:189544.
29. Zhou Q, Zhou L, Chen X, Chen Q, Hao L. Crosstalk between the intratumoral microbiota and the tumor microenvironment: new frontiers in solid tumor progression and treatment. Cancer Rep. 2024;7:e70063.
30. Liu W, Li Y, Wu P, et al. The intratumoral microbiota: a new horizon in cancer immunology. Front Cell Infect Microbiol. 2024;14:1409464.
31. Zhong L, Li Q, Xiong T, et al. Spatial omics in gastrointestinal oncology: recent advances, therapeutic insights, and clinical translation. J Cancer. 2026;17:515-23.
32. See JE, Barlow S, Arjumand W, DuBose H, Segato Dezem F, Plummer J. Spatial omics: applications and utility in profiling the tumor microenvironment. Cancer Metastasis Rev. 2025;44:87.
33. Lv B, Zhao Y, Li G, et al. Tumor-resident intracellular bacteria scavenger activated in situ vaccines for potent cancer photoimmunotherapy. Adv Healthc Mater. 2025;14:e2404271.
34. Wang B, Ding H, Li Y, Zhao X, Ge P. Immune-excluded and immune-suppressive tumor microenvironments: mechanisms, spatial biomarkers, and therapeutic rewiring. Front Oncol. 2026;16:1855429.
